Quantitative evaluation of research results Is the foundation of much scientific research. The Biostatistics Core provides resources to assist in the planning, conduct and analysis of research in such a way that quantitative analyses are appropriate and illuminating. The core also assists In the dissemination of appropriate information both within and external to the Siteman Cancer Center (SCC). Services ofthe Biostatistics Core include: Participating during the design phase of protocols, including the selection of the appropriate study design, primary endpoints, sample size and statistical model. Triage to the appropriate core member. Collaborating in the analysis of data collected for cancer-related protocols conducted by SCC members. The protocols range from analysis of large-scale outcomes research protocols to clinical trials to basic science data. Triage to the appropriate core member. Being available for consulting on the appropriate use of statistical models for all cancer-related studies conducted by SCC members. Providing statistical and methodological review of proposals submitted for SCC internal funding mechanisms. Collaborating in the publication of study results. Providing biostatistical and methodological review of all protocols submitted to the PRMC for full review ' Providing statistical consultation to other SCC Cores with respect to their missions. Important links exit for the Health Behavior, Communications and Outreach Core, the Clinical Trials Core, the High Throughput Screening Core, the Multiplexed Gene Analysis Core, the Small Animal Cancer Imaging Core and the Hereditary Cancer Core. Work with the Bioinformatics Core in deploying CaBIG compatible tools for the collection and extraction of clinical data and the linking with associated tissue samples. Providing informatics services in manipulation and merging of existing clinical electronic data sets.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261

Showing the most recent 10 out of 1109 publications